Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer.

Gabriel K, Ingram A, Austin R, Kapoor A, Tang D, Majeed F, Qureshi T, Al-Nedawi K.

PLoS One. 2013 Jul 25;8(7):e70047. doi: 10.1371/journal.pone.0070047. Print 2013.

2.

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.

Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR.

PLoS One. 2012;7(10):e46737. doi: 10.1371/journal.pone.0046737. Epub 2012 Oct 16.

3.

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.

Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, Clark J, Berney DM, Møller H, Scardino P, Sangale Z; Transatlantic Prostate Group.

Br J Cancer. 2013 Jun 25;108(12):2582-9. doi: 10.1038/bjc.2013.248. Epub 2013 May 21.

4.

Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes.

Lázaro-Ibáñez E, Sanz-Garcia A, Visakorpi T, Escobedo-Lucea C, Siljander P, Ayuso-Sacido A, Yliperttula M.

Prostate. 2014 Oct;74(14):1379-90. doi: 10.1002/pros.22853. Epub 2014 Aug 11.

5.

Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer.

Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, De Marzo AM, Platz EA, Netto GJ.

Mod Pathol. 2012 Nov;25(11):1543-9. doi: 10.1038/modpathol.2012.104. Epub 2012 Jun 8.

6.

Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth.

Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, Saunus J, Lakhani S, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D.

Nature. 2015 Nov 5;527(7576):100-104. doi: 10.1038/nature15376. Epub 2015 Oct 19.

7.

An optimized procedure for exosome isolation and analysis using serum samples: Application to cancer biomarker discovery.

Li M, Rai AJ, DeCastro GJ, Zeringer E, Barta T, Magdaleno S, Setterquist R, Vlassov AV.

Methods. 2015 Oct 1;87:26-30. doi: 10.1016/j.ymeth.2015.03.009. Epub 2015 Mar 24.

PMID:
25814440
8.

Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.

Logozzi M, Angelini DF, Iessi E, Mizzoni D, Di Raimo R, Federici C, Lugini L, Borsellino G, Gentilucci A, Pierella F, Marzio V, Sciarra A, Battistini L, Fais S.

Cancer Lett. 2017 Sep 10;403:318-329. doi: 10.1016/j.canlet.2017.06.036. Epub 2017 Jul 8.

PMID:
28694142
9.

Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer.

Neeb A, Hefele S, Bormann S, Parson W, Adams F, Wolf P, Miernik A, Schoenthaler M, Kroenig M, Wilhelm K, Schultze-Seemann W, Nestel S, Schaefer G, Bu H, Klocker H, Nazarenko I, Cato AC.

Oncotarget. 2014 Sep 30;5(18):8681-9.

10.

Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells.

Liu T, Mendes DE, Berkman CE.

Int J Oncol. 2014 Mar;44(3):918-22. doi: 10.3892/ijo.2014.2256. Epub 2014 Jan 10.

11.

Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.

Lu TL, Huang YF, You LR, Chao NC, Su FY, Chang JL, Chen CM.

Am J Pathol. 2013 Mar;182(3):975-91. doi: 10.1016/j.ajpath.2012.11.025. Epub 2013 Jan 9.

PMID:
23313138
12.

βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.

Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T, Wilczak W, Sirma H, Simon R, Sauter G, Minner S, Quaas A.

Am J Pathol. 2014 Mar;184(3):609-17. doi: 10.1016/j.ajpath.2013.11.007. Epub 2013 Dec 28.

PMID:
24378408
13.

Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.

Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T.

Am J Pathol. 2012 Aug;181(2):401-12. doi: 10.1016/j.ajpath.2012.04.026. Epub 2012 Jun 13.

PMID:
22705054
14.

Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: Application for prostate cancer diagnostic.

Samsonov R, Shtam T, Burdakov V, Glotov A, Tsyrlina E, Berstein L, Nosov A, Evtushenko V, Filatov M, Malek A.

Prostate. 2016 Jan;76(1):68-79. doi: 10.1002/pros.23101. Epub 2015 Sep 29.

PMID:
26417675
15.

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL.

Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50.

16.

Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.

Kato T, Mizutani K, Kameyama K, Kawakami K, Fujita Y, Nakane K, Kanimoto Y, Ehara H, Ito H, Seishima M, Deguchi T, Ito M.

Urol Oncol. 2015 Sep;33(9):385.e15-20. doi: 10.1016/j.urolonc.2015.04.019. Epub 2015 May 28.

PMID:
26027763
17.

High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.

Grupp K, Wilking J, Prien K, Hube-Magg C, Sirma H, Simon R, Steurer S, Budäus L, Haese A, Izbicki J, Sauter G, Minner S, Schlomm T, Tsourlakis MC.

Eur J Cancer. 2014 Mar;50(4):852-61. doi: 10.1016/j.ejca.2013.12.003. Epub 2013 Dec 28.

PMID:
24380696
18.

Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer.

Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A.

Br J Cancer. 2009 May 19;100(10):1603-7. doi: 10.1038/sj.bjc.6605058. Epub 2009 Apr 28.

19.

Complex-I Alteration and Enhanced Mitochondrial Fusion Are Associated With Prostate Cancer Progression.

Philley JV, Kannan A, Qin W, Sauter ER, Ikebe M, Hertweck KL, Troyer DA, Semmes OJ, Dasgupta S.

J Cell Physiol. 2016 Jun;231(6):1364-74. doi: 10.1002/jcp.25240. Epub 2015 Nov 24.

PMID:
26530043
20.

Supplemental Content

Support Center